Omeprazole mosapride treatment of reflux esophagitis in 50 Cases.docVIP

Omeprazole mosapride treatment of reflux esophagitis in 50 Cases.doc

  1. 1、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。。
  2. 2、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载
  3. 3、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
  4. 4、该文档为VIP文档,如果想要下载,成为VIP会员后,下载免费。
  5. 5、成为VIP后,下载本文档将扣除1次下载权益。下载后,不支持退款、换文档。如有疑问请联系我们
  6. 6、成为VIP后,您将拥有八大权益,权益包括:VIP文档下载权益、阅读免打扰、文档格式转换、高级专利检索、专属身份标志、高级客服、多端互通、版权登记。
  7. 7、VIP文档为合作方或网友上传,每下载1次, 网站将根据用户上传文档的质量评分、类型等,对文档贡献者给予高额补贴、流量扶持。如果你也想贡献VIP文档。上传文档
查看更多
Omeprazole mosapride treatment of reflux esophagitis in 50 Cases

 PAGE \* MERGEFORMAT 7 Omeprazole mosapride treatment of reflux esophagitis in 50 Cases [Abstract] Objective To observe the omeprazole mosapride treatment of reflux esophagitis patients. Methods 50 patients with reflux esophagitis were randomly divided into 2 groups 25 patients: treatment group: Ogilvy amp; Mather pull-yl 20mg, once daily oral administration, mosapride 5 mg, 3 times a day orally, the control group: mosapride 5 mg, 3 times a day orally. Both groups were observed after 4 weeks of treatment efficiency and clinically significant efficient. the treatment group showed significantly higher efficiency and efficiency (P lt;0.05. Conclusions Omeprazole mosapride treatment of reflux esophagitis better efficacy than the single drug. [Keywords:] mosapride omeprazole reflux esophagitis Reflux esophagitis is an intractable digestive diseases, due to excessive stomach, duodenal contents into the esophagus caused by anti-acid reflux, difficulty swallowing and other symptoms, and lead to esophageal mucosal erosion, ulcers and other diseases, symptoms or tissue damage caused by the clinical is not uncommon. It is reported that reflux esophagitis gastroesophageal reflux disease accounts for about 48% to 79% [1]. reflux esophagitis patients as the main driving force obstacles mosapride in the digestive tract prokinetic agent, can selectively act on neurons in the gastrointestinal smooth muscle 5-HT 4 (5 HT4 receptors, cholinergic gastrointestinal tract through the middle of excitatory neurons and myenteric plexus of 5 HT4 receptor, to promote the release of acetylcholine, thereby enhancing the digestive tract (stomach and intestinal motility, gastrointestinal motility is a novel full of drug. We apply mosapride combined with proton pump inhibitors omeprazole treatment of reflux esophagitis, 50 patients achieved satisfactory results, are as follows. 1 Materials and Methods 1.1 General information select from March 2005 to June 2008 due to reflux esoph

文档评论(0)

jiupshaieuk12 + 关注
实名认证
文档贡献者

该用户很懒,什么也没介绍

版权声明书
用户编号:6212135231000003

1亿VIP精品文档

相关文档